Allergan price target raised to $202 from $181 at Morgan Stanley. Morgan Stanley analyst David maintained an Overweight rating on Allergan and raised his price target to $202 from $181. In a research note to investors, Risinger says the company’s upcoming Aesthetics Investor Day on September 14 should help investors “appreciate” the durability of the franchise. Additionally, the analyst experts ubrogepant for acute migraine safety data will be “supportive” of approval in 2H, with an FDA filing in early 2019 and launch in early 2020, and says there is “upside” beyond his base case if rapastinel for severe depression Phase 3 data is compelling in 1H19. Risinger believes the pipeline newsflow on migraine and depression could potentially benefit Allergan’s stock multiple.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.